The first standard-of-care drug for treating COVID-19 may be coming sooner than we think.

Results from an interim analysis of COVID-19 patients receiving Gilead Sciences' (NASDAQ:GILD) antiviral drug Remdesivir in phase 3 clinical trials conducted by the National Institute of Allergy and Infectious Diseases (NIAID) were announced April 29. They showed that the drug met its primary endpoint in improving patients' recovery, but failed to achieve statistical significance in improving patients' survival.

Does this mean Remdesivir is unable to save lives? Or is there something investors and skeptics have overlooked?